rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Tempest Therapeutics, Inc.

TPST · Nasdaq

Health CareBiotechnologyNot moving yet

TPST stood above a rising 150-day average in 4 of the last 52 weekly readings, and has been out of that trend for the last 48 weeks. It is 53.8% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 48
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$2.0M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
19 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 4 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$1.9MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Matthew AngelCEO and Presidentbought231,482at $2.1624 Mar 2026filed 23 Jun 2026
Matthew AngelCEO and Presidentbought231,48224 Mar 2026filed 23 Jun 2026
Matthew AngelCEO and Presidentbought231,48224 Mar 2026filed 23 Jun 2026
Matthew AngelCEO and Presidentbought231,482at $2.1624 Mar 2026filed 25 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders19+0 on the quarter
New · exited4 · 4
Reported value$1.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
SABBY MANAGEMENT, LLCadded · filed 14 Aug 2026511,286$568K+493,430+2763.4%
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 2026233,888$260K00.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202686,625$96K-365−0.4%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202668,908$76K00.0%
BlackRock, Inc.unchanged · filed 7 Aug 202639,068$43K00.0%
Squarepoint Ops LLCnew · filed 14 Aug 202630,900$34K+30,900
NORTHERN TRUST CORPadded · filed 13 Aug 202620,136$22K+6,083+43.3%
CITADEL ADVISORS LLCnew · filed 14 Aug 202619,820$22K+19,820
UBS Group AGadded · filed 13 Aug 20265,636$6,255+1,103+24.3%
Tower Research Capital LLC (TRC)added · filed 11 Aug 20263,922$4,353+1,132+40.6%
31 Mar 2025 – 30 Jun 2026
31118Mar 25Jun 25Dec 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Nancy Freda Smith Company insiderDirector · last 22 Sep 20260 · 0
John D. Yee Company insiderDirector · last 4 Jun 20260 · 0
William Drake Richey Company insiderDirector · last 4 Jun 20260 · 0
Justin Trojanowski Company insiderCorporate Controller · last 31 Mar 20261 · 0
Nicholas Maestas Company insiderChief Financial Officer · last 31 Mar 20260 · 0
Matthew Angel Company insiderCEO and President · last 24 Mar 20262 · 0
Christine A. Pellizzari Company insiderDirector · last 27 Jan 20260 · 0
Geoffrey Nichol Company insiderDirector · last 27 Jan 20260 · 0
Michael Raab Company insiderDirector · last 27 Jan 20260 · 0
Ronit Simantov Company insiderDirector · last 27 Jan 20260 · 0
Samuel Whiting Company insiderChief Medical Officer · last 2 Jan 20252 · 0
Stephen R. Brady Company insiderPresident and CEO · last 2 Jan 20251 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-195%
Share count trendFY 2025 · to 25 Mar 2026191%
Cash and equivalentsFY 2025 · to 31 Dec 2025$7.7M
Free cash flowFY 2025 · to 31 Dec 2025−$26.8M

Analyst forecasts

No analyst forecasts yet.